Table 1.
OND | Control | Total | p value | |
---|---|---|---|---|
Sample size | 40 | 40 | 80 | — |
Age | 25.8 ± 8.5 | 29.4 ± 9.5 | 27.6 ± 9.5 | 0.1 |
Gender (m : f) | 31 : 9 | 27 : 13 | 58 : 22 | 0.3 |
BMI | 24.2 ± 3.4 | 23.3 ± 2.6 | 23.8 ± 3.1 | 0.9 |
ASA (I : II) | 35 : 5 | 33 : 7 | 68 : 12 | 0.5 |
Systolic BP | 116.4 ± 8.5 | 117.4 ± 9.1 | 116.9 ± 8.9 | 0.6 |
Diastolic BP | 74.5 ± 8.4 | 74.5 ± 6.9 | 74.5 ± 7.6 | 0.9 |
HR | 85.7 ± 5.1 | 83.1 ± 5.3 | 84.4 ± 5.4 | 0.06 |
O2 saturation | 99.4 ± 0.9 | 99.0 ± 0.2 | 99.7 ± 0.7 | 0.001 |
VAS pain | 4.2 ± 0.8 | 4.1 ± 1.0 | 4.0 ± 1.9 | 0.8 |
OND, ondansetron; BMI, body mass index; m : f, male-to-female; ASA, American Society of Anesthesiologists, BP, blood pressure; HR, heart rate; VAS, visual analog scale.